Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal DiseasesBOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- Memento Medicines, Inc., a privately-held biotech company developing biologic therapies for retinal diseases, today announced the completion of a $93M Series A financing round co-led by Forbion, RA Capital Management and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital. In connection with the financing, Memento also announced that it has entered into an exclusive license agreement with MabTics Co., Ltd. and Curacle Co., Ltd. to obtain worldwide rights to MMT-205. MMT-205, previously known as MT-103, is a bispecific antibody that activates Tie2 and inhibits VEGF, two clinically validated targets that play a central role in the pathogenesis of retinal and vascular diseases. Under the terms of the license agreement, MabTics and Curacle have received upfront consideration comprising cash payments and equity in Memento and are also eligible for additional development, regulatory, and commercial milestones and tiered royalties on net sales.
